London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

Enter efimosfermin alfa, described as a phase 3-ready, once-monthly injectable fibroblast growth factor 21 (FGF21) analogue with potential across steatotic liver diseases (SLD), including MASH and ...

Emerging therapies for liver fibrosis include Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Lanifibranor (IVA337), Aramchol, WEGOVY (semaglutide 2. ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed. Among 65 ...

Additionally, GSK has acquired efimosfermin alfa, a treatment for steatotic liver disease, from Boston Pharmaceuticals for $1.2 billion upfront. The drug, in phase III trials, is anticipated to launch ...

Additionally, GSK has acquired efimosfermin alfa, a treatment for steatotic liver disease, from Boston Pharmaceuticals for $1.2 billion upfront. The drug, in phase III trials, is anticipated to ...

GSK buys liver drug for $1.2 billion GSK is spending $1.2 billion up front and promising up to $800 million more for the rights to a liver disease drug candidate called efimosfermin alfa.

British pharmaceutical company GSK (GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash.

In phase II studies, efimosfermin alfa has shown the potential to reverse liver fibrosis and stop its progression in patients with metabolic dysfunction-associated steatohepatitis (“MASH”), a ...